Advanced Search

 

Study ID Status Title Patient Level Data
200794 Completed A Pilot Study to Measure Force Recovery and Protein Synthetic Rates After Unilateral Eccentric Exercise in Healthy Males Volunteers Unaccustomed to Eccentric Exercise
200799 Completed Study to compare immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose presentation to the licensed Synflorix™ (10Pn-PD-DiT) vaccine when co-administered with DTPw-combination vaccine in healthy infants
200806 Completed Immunogenicity and safety study of GSK Biologicals’ quadrivalent influenza vaccine (GSK2282512A) in children 6 to 35 months of age Study Listed on ClinicalStudyDataRequest.com
200807 Recruiting A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents
200808 Recruiting A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa
200812 Completed A phase IIIB, 24-week randomised, double-blind study to compare ‘closed’ triple therapy (FF/UMEC/VI) with 'open' triple therapy (FF/VI + UMEC), in subjects with chronic obstructive pulmonary disease (COPD)
200820 Completed A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared with Vilanterol Inhalation Powder (VI) 25 mcg Once Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
200852 Withdrawn A Double-Blind Safety and Efficacy Study of GSK2894512 Cream versus Vehicle in the Treatment of Adult Plaque Psoriasis
200858 Terminated A Phase I Open-label, Dose Escalation Study to Investigate The Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects with Relapsed/Refractory Small Cell Lung Carcinoma
200860 Completed Clinical assessment of fluticasone propionate/ salmeterol xinafoate HFA MDI in 6-month to 4-year-old Japanese patients with bronchial asthma
200862 Completed A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects with Severe Eosinophilic Asthma on Markers of Asthma Control Study Listed on ClinicalStudyDataRequest.com
200869 Recruiting The Burden of Rhinitis Symptoms in Chinese Patients with Allergic Rhinitis
200870 Recruiting The Mepolizumab Pregnancy Exposure Study: a VAMPSS post marketing surveillance study of Mepolizumab safety in pregnancy
200879 Recruiting A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed with an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
200883 Recruiting Evaluation Of Use of Belimumab in Clinical Practice SEttings (OBSErve) Observations from Spain
200884 Completed A Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblinded) Study to Investigate Protective Effects of GSK1278863 on Eccentric Exercise Induced Muscle Damage in Healthy Male Volunteers
200894 Not yet recruiting Study 200894: A double-blind, double-dummy, randomized, parallel group, placebo-controlled superiority study to evaluate the efficacy and safety of tafenoquine (SB-252263, WR238605) co-administered with dihydroartemisinin-piperaquine (DHA-PQP) for the radical cure of Plasmodium vivax malaria
200896 Active, Not Recruiting Reasons and Consequences for Discontinuation and Adherence with Daily Glucagon-like Peptide-1 Therapies in Type 2 Diabetes Mellitus Patients in the United States
200901 Completed A Phase I, Open label, Randomized, Three period, Fixed Sequence Crossover study to Evaluate the Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (200901)
200902 Completed A Randomised, Double-Blind (Sponsor Unblind), Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Single Ascending Doses of a Fully Humanized Anti-IL-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers
200909 Completed A single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK1550188 in Chinese subjects with Systemic Lupus Erythematosus (SLE)
200911 Recruiting A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose ranging study to evaluate the antiviral effect, safety, tolerability and pharmacokinetics of Cobicistat-boosted GSK2838232 monotherapy over 10 days in HIV-1 infected treatment-naive adults
200912 Terminated A Double-Blind, Randomized, Placebo-Controlled, Continuation Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 with and without Ritonavir, and to Evaluate Different Formulations of GSK2838232, in Healthy Subjects
200919 Completed An Open-label Phase 1 Study to Evaluate the Effects of Dabrafenib (GSK2118436) on the Single Dose Pharmacokinetics of an OATP1B1/1B3 Substrate and of a CYP3A4 Substrate in Subjects with BRAF V600 Mutation Positive Tumors
200920 Completed Skin Irritation Study of GSK2894512 Cream-An Evaluator-Blinded Study to Evaluate the Skin Irritation of GSK2894512 Cream and Placebo following Single Application by Simple-Patch Test and Photo-Patch Test, and Repeat Application under non-occlusive condition in Healthy Japanese Subjects Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.